- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Focus on Women's Health
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
COVID-19 Vaccine Updates
COVID-19 Vaccine Updates
As COVID-19 vaccines are distributed, there are complex regulatory and logistical challenges to navigate. In addition, uncertainties around reimbursement, workplace policies and liabilities loom. This online resource is a go-to for staying informed on the COVID-19 vaccines and related legal and regulatory developments.
Please select from our options below related to our links and resources of recent research related to the various rollout initiatives as well as an archive of our routine updates of news headlines and government initiatives related to the same.
Follow us:
Subscribe to receive real-time blog updates via RSS feed. Feeder is only one such tool available, so you may perform a search or consult your technical support team to explore alternatives. King & Spalding does not endorse or provide technical support in connection with any RSS feed reader or browser products, vendors or consultants, and any mention of products or services, or provision of related website links is for informational purposes only. To use the “Feeder” RSS feed reader, you may install an internet browser extension, e.g., for Google Chrome or Microsoft Edge. After install, click the orange RSS icon in your browser menu and continue with or without signing up for a Feeder account. Click the plus + sign to add a feed, then copy and paste our COVID-19 Vaccine Updates blog feed URL - https://www.kslaw.com/blogs/covid-19-vaccine-updates.rss - into the search field. Click Search, then Follow and choose your preferred update and notification settings, then click Done. Click Home to view and access all blog posts. Bookmark the Feeder Home page to quickly return to this page later.
February 23, 2021
Increased Reliance on the DPA to Fight COVID-19 Has Major Impact on Supplies of Other Drugs and Therapies
Defense Production Act
February 22, 2021
FDA Issues Additional Guidance for Medical Product Developers Addressing Virus Variants
Regulatory Landscape
February 22, 2021
Malign Cyber Actors Target COVID-19 Vaccine Supply Chain
Advocacy
February 22, 2021
CDC Publishes Resources from the National Forum on COVID-19 Vaccine
Regulatory Landscape
February 22, 2021
February 22 Vaccine Rollout Updates from the White House COVID-19 Response Team
Regulatory Landscape
February 19, 2021
White House COVID-19 Response Team Addresses Impact of Severe Weather on Vaccine Rollout
Regulatory Landscape
February 19, 2021
CDC Publishes Safety Monitoring Data for the First Month of Vaccination Administration
Regulatory Landscape
February 19, 2021
U.N. Secretary-General Urges Countries to Remedy Inequity in Vaccine Distribution
Advocacy
February 17, 2021
White House COVID-19 Response Team Addresses Johnson & Johnson Vaccine Rollout Plans
Regulatory Landscape
February 17, 2021
CDC Publishes Reports on COVID-19 Variants
Regulatory Landscape
February 17, 2021
February 16 Vaccine Rollout Updates from the White House
Regulatory Landscape
February 17, 2021
Vaccine Shipments to Maryland and Elsewhere Delayed by Winter Storm
Liabilities
Contacts
Amy Garrigues
Partner
+1 312 764 6932
Elizabeth Lindquist
Partner
+1 202 626 5585
Steve Cave
Partner
+1 703 245 1017
Mark Polston
Partner
+1 202 626 5540
Amanda Sonneborn
Partner
+1 312 764 6940
David Farber
Partner
+1 202 626 2941
Juliet McBride
Partner
+1 713 276 7448
Chris Kenny
Partner
+1 202 626 9253